Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| The year-over-year improvement in adjusted EBITDA of $15.1 million is important as our bank loan covenants is calculated on a trailing 12-month basis and therefore Inotiv has further improved its financial flexibility for the quarter starting January 1, 2024 |
| If we took out -- if we backed out Rockville sales and margins for this last quarter, we still had increasing sales and we actually would have improved our DSA margins |
| We see our ability to expand our service business and take advantage of recent expansion efforts and leveraging our fixed cost structure as one of the biggest opportunities for future margins and earning improvements |
| As noted in our year-end conference call, last quarter, our promise to shareholders, customers, employees has been to guide Inotiv towards becoming a leading midsize CRO in the marketplace through transformative acquisitions and build out new services, which ultimately will expand upon our contract research service capabilities |
| By taking direct control of our transportation operations, we expect to further reduce costs and achieve key efficiencies to strengthen internal operations, improve our outgoing supply chain and further improve service quality for clients |
| This will allow us to better service our customers’ demand and new complementary services and create a platform, which will support growth and allow us to leverage our fixed cost structure and enhanced margins |
| And I think over the course of the year, we still and going into 2025, we’re in a really pretty good position |
| With critical operational groundwork achieved in the past 18 months, we firmly expect to see success in our strategic initiatives in improving efficiency to positively impact our top and bottomlines |
| We have continued to complete new assays and are pleased with the continued growth and startup of our new genetic toxicology and biotherapeutics business in Rockville -- in our Rockville, Maryland facility |
| We estimate that once the expansion of Hillcrest, with the consolidation of Blackthorn and the renovations for the two new customer contracts are complete, we expect a small research model and services in Europe to see annual revenue growth of approximately 15% -- annual revenue growth and approximately 15% improvement in our margins |
| Additionally, our conversion rate, which is our ability to convert our backlog to sales, has improved over Q1 fiscal 2023 |
| While we believe we are in a much better position than we were a year ago, we feel we can continue to make further improvements |
| We know we’re running probably 25% of the capacity of that site at the moment, we’re pleased with the way that it has come on Board and that we’re still validating those assays, and we’re very pleased with some of the backlog that we grew in that site last quarter, which is a real positive sign for us in that site going forward |
| As our new services start to come online and we begin to fill newly added capacity, we believe we will be able to boost our DSA margins from the mid-30% range in 2024 to a level in line with our long-term targets of going consistently into the upward 30% range |
| We -- it was a very good quarter and I believe last quarter was a 0.65, and then this was a 1.46 or 1.4 plus |
| So we’ll hope that, it would be nice to continue these trends, but 1.46 was a surprise, a very pleasant surprise and I think a great trend |
| We are pleased that we were able to improve adjusted EBITDA by $15.1 million over the last year’s quarter and with the progress that was made to complete the capacity expansions for the DSA segment to increase revenue and improve margins, and the significant progress made on the site optimization plans for the RMS segment |
| We believe we are now positioned more strongly for the current macro environment and well-positioned to participate in a wider recovery in our industry, which will allow us to further accelerate our growth and improve margins on an incremental basis |
| Our first quarter saw some very good awards and positive momentum, and the improvements in the DSA backlog exceeded our expectations |
| We believe we are well positioned to increase our sales volume in 2024, driven by greater cross-selling to our existing customers, expanding our sales team, focusing our market efforts and building our brand recognition |
| However, pricing for NHPs was still much stronger so overall NHP sales and margins and therefore RMS sales and margins remained higher than a year ago |
| We believe this shift would be favorable for our NHP business as we could increase the predictability of our NHP revenue and improve the management of our working capital |
| I think this year the supply is much better than it was last year at this time and I think people now learned quite a bit from that and said, okay, we want to now have long-term suppliers over multiple years and that would work well for us, because we would have increased predictability and we could -- our capital needs -- working capital needs would be much more predictable |
| These include the conclusion of our site optimization plan, continuing site infrastructure and animal welfare improvements in our RMS business; continuing to evaluate and improve our RMS transportation operations and service based on our new site footprint, which should allow us to further reduce expenses and improve client services; further expand our NHP supply and customer base; focus on expanding our customer base while continuing to improve and provide exceptional client services; continuing to further leverage our scale and capabilities to reduce outsourcing costs, to enhance our competitive profile and increase the speed of innovation for the discovery and development process for our customers |
| So I think that’s a real positive |
| And there is -- I’m really pleased with the collaboration |
| But very pleased with it, nonetheless |
| We believe that our strategic efforts will enable us to broaden our customer base and better serve these customers through innovation and development of nimble solutions and custom offerings |
| In the meantime, we will continue our efforts to grow our reputation, become a leading midsize CRO provider of choice |
| We continue to enhance and build an organization delivering innovation and solutions for drug discovery and development |
| Statement |
|---|
| And in particular, I mentioned, Rockville and Maryland site is that, Rockville, Maryland site has negative margins right now |
| Our DSA operating income was down for the quarter compared to the same quarter in 2023 due to increased costs associated with the development of new services |
| In the first fiscal quarter of 2024, the total number of NHPs we sold was down 20% compared to the same period a year ago |
| DSA non-GAAP operating income in Q1 of fiscal 2024 was unfavorably impacted by the increased costs at our new facility in Rockville, Maryland, as this facility is close to being fully operational and general price increases seen for research models, operating supplies and compensation and benefits |
| We also experienced client delays and studies for this facility, and therefore, did not realize any revenue from the expanded facility in fiscal Q1 of this year |
| Well, that’s a great question and for me it’s not going to happen soon enough, because we still are investing in startup costs there and the margins are negative at the moment |
| Non-GAAP operating income for our DSA segment in the first quarter decreased to $6.9 million or 15.5% of segment revenue from $7.9 million or 19.1% of segment revenue in last year’s first quarter |
| So that’s another reason why margins were down a little bit towards at the end of 2022 |
| Cancellation rates in Q1 2024 were less than half of that we observed in the immediately prior quarter and the lowest we have seen since Q3 fiscal 2022 |
| In last quarter’s conference call, we indicated that NHP prices were expected to come down from the highs we saw in Q4 of fiscal 2023 |
| We are still seeing some projects get delayed which can impact our quarterly revenue |
| We did experience some delays during Q1 in completing this expansion and validating this new facility |
| These increases are partially offset by lower volume of NHP sales and a decrease in revenue for small research models due to lower demand |
| And some of the challenges with those contracts is that they were fixed price contracts that we were buying on the spot market at the end of the last year |
| Operating loss for the first quarter of fiscal 2024 was $9.4 million, compared to a loss of $90.6 million from last year’s first quarter, which included $66.4 million of goodwill impairment loss |
| We did see the NHP pricing on average come down roughly 18% in Q1 of fiscal 2024 versus Q4 of fiscal 2023, with Q1 of 2024 closer to the average unit price for all of fiscal 2023, including the fiscal quarter -- the first fiscal quarter of last year |
| Consolidated net loss attributable to common shareholders in the first quarter of fiscal 2024 totaled $15.4 million or a $0.60 loss per diluted share |
| Additionally, the planned closures of 11 facilities over the last 18 months created substantial severance costs, significant startup costs related to transfer of production between sites, starting new services and expanding facilities |
| However, it’s not -- that is a lot less predictable and we saw that last year |
| And so that’s one of the reasons why we make sure we give annual guidance and not quarterly guidance, because I think we could see some significant fluctuations in the NHPs from quarter-to-quarter |
Please consider a small donation if you think this website provides you with relevant information